Aquapharm and Dundee University Sign Research Collaboration to find Marine Compounds to target Alzheimer’s
Aquapharm Biodiscovery announced it has signed a research agreement with Dundee University to help it develop new drugs based on marine natural products that may help in the fight against Alzheimer’s.
Alzheimer's is a disease marked by the formation of insoluble protein aggregates in the brain with associated progressive degeneration of the neurons. The collaboration is aimed at O-GIcNAcase, a well-documented target for Alzheimer’s, that modulates the solubility of the protein in these aggregates but that has been difficult to target with conventional small-molecule libraries. It therefore forms an ideal opportunity to demonstrate that Aquapharm’s growing collection of novel and diverse marine-derived compounds and scaffolds can modulate a clinically attractive but pharmacologically challenging target for a disease for which new solutions are urgently required.
Aquapharm will be working with Professor Daan van Aalten, Professor of Biological Chemistry at the University, who brings to the collaboration expertise in studying the structural aspects and mechanism of protein-carbohydrate interactions, and applies this knowledge to design molecules that modulate these interactions in biological systems as research tools or leads for the development of chemotherapeutics.
Aquapharm will fund research in Professor van Aalten’s labs and will provide access to extracts from Aquapharm’s culture collection of marine micro-organisms to screen and “mine” for individual active compounds. Dundee will provide knowledge transfer of the O-GlcNAcase high-throughput screens to Aquapharm to allow the company to conduct screening work to run alongside the academic programme.
Initial results from this research agreement are expected during 2011.
Other news from the department science

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
How old memories fade away - Discovery of a gene essential for memory extinction could lead to new PTSD treatments
Can corn be taught to fix its own nitrogen?
Balzan Prizes 2010: 1 Million Francs to stem cell researcher
Frost & Sullivan: The biobanking community to increasingly require innovative products in bio-storage applications
Merck awards its 2017 Grant for Fertility Innovation (GFI) to research projects - Professor Lunenfeld honored with Merck Lifetime Achievement Award

Merck invests more than € 300 Million in new life science production site in South Korea - Site to supply products to customers for development and production of biologics
Endogenous Infection Marker Guides Antibiotic Therapy
Epigenomics AG Successfully Validates Lung Cancer Test in Clinical Trial
Oriola-KD Corporation has completed the sale of its Healthcare Trade business to Mediq N.V.

A medical device for safe growth of neural stem cells using nanotechnology
